All Inventions from NIAID

  • Tau RT-QuIC: Ultrasensitive Assays for the Detection of Tau Seeding Activity Associated with Tauopathies
    •
       Ref: E-015-2017-0 | Updated: Oct 14, 2020 | NIAID
  • Methods for Dagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153...
    •
       Ref: E-085-2018-0 | Updated: Sep 21, 2020 | NIAID
  • Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection
    •    Ref: E-001-2017-0 | Updated: Sep 21, 2020 | NIAID
  • Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine
    •
       Ref: E-293-2011-0 | Updated: Aug 3, 2020 | NIAID
  • Monoclonal Antibodies Against Bacillus Anthracis Antigens
    •
       Ref: E-146-2004-0 | Updated: Jul 6, 2020 | NIAID
  • Recombinant Proteins Of A Pakistani Strain Of Hepatitis E And Their Use In Diagnostic Methods And Vaccines
    •
       Ref: E-141-1992-2 | Updated: Jul 6, 2020 | NIAID
  • Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences
    •
       Ref: E-032-2018-0 | Updated: Jul 6, 2020 | NIAID
  • Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A
    •
       Ref: E-180-2006-0 | Updated: Jul 6, 2020 | NIAID
  • Monoclonal Antibodies that Neutralize Norovirus
    •
       Ref: E-226-2011-0 | Updated: Jul 6, 2020 | NIAID
  • Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis,...
    •
       Ref: E-017-2001-0 | Updated: Jul 6, 2020 | NIAID
  • Protein Nanoparticles for Antigen Display in Vaccines
    •
       Ref: E-005-2017-0 | Updated: Jul 6, 2020 | NIAID
  • Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E
    •
       Ref: E-203-1997-0 | Updated: Jul 6, 2020 | NIAID
  • Monoclonal Antibodies Against Orthopoxviruses
    •
       Ref: E-145-2004-3 | Updated: Jul 6, 2020 | NIAID
  • Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
    •
       Ref: E-195-2014-0 | Updated: Jul 6, 2020 | NIAID
  • Vaccine for Dengue Virus
    •
       Ref: E-171-1988-1 | Updated: Jul 6, 2020 | NIAID
  • A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of...
    •
       Ref: E-029-2007-0 | Updated: Jul 6, 2020 | NIAID
  • Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses
    •
       Ref: E-033-2018-0 | Updated: Jul 6, 2020 | NIAID
  • Diagnostic Reagents And Vaccines For Multiple Genotypes Of Hepatitis C Virus
    •
       Ref: E-120-1993-0 | Updated: Jul 6, 2020 | NIAID
  • Middle East Respiratory Syndrome Coronavirus Antibodies
    •
       Ref: E-239-2014-0 | Updated: Jun 24, 2020 | NIAID
  • Prefusion Coronavirus Spike Proteins and Their Use
    •
       Ref: E-234-2016-0 | Updated: Apr 8, 2020 | NIAID
  • Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface...
    •
       Ref: E-185-2018-0 | Updated: Mar 9, 2020 | NIAID
  • Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV...
    •
       Ref: E-034-2018-0 | Updated: Mar 9, 2020 | NIAID
  • Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof
    •
       Ref: E-061-2018-0 | Updated: Mar 9, 2020 | NIAID
  • A High-Yield Perfusion-Based Transient Gene Expression Bioprocess
    •
       Ref: E-187-2018-0 | Updated: Dec 2, 2019 | NIAID
  • Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene...
    •
       Ref: E-018-2010-0 | Updated: Oct 9, 2019 | NIAID
  • Recombinant HIV-1 Envelope Proteins and Their Use
    •
       Ref: E-240-2017-0 | Updated: Sep 5, 2019 | NIAID
  • Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene
    •
       Ref: E-062-2012-0 | Updated: Aug 27, 2019 | NIAID
  • Recombinant Nipah F Proteins and Their Use
    •
       Ref: E-050-2018-0 | Updated: Aug 21, 2019 | NIAID
  • HIV targets CD62L on central memory T cells through viral envelope glycans for adhesion and induces selectin...
    •
       Ref: E-261-2015-0 | Updated: Jul 31, 2019 | NIAID
  • Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8
    •
       Ref: E-133-2015-0 | Updated: Nov 19, 2018 | NIAID
  • Fusion Glycoprotein Vaccine for Human Metapneumovirus
    •
       Ref: E-260-2014-0 | Updated: Oct 29, 2018 | NIAID
  • Use of Rostafuroxin to Inhibit Viral Infection
    •
       Ref: E-202-2018-0 | Updated: Oct 25, 2018 | NIAID
  • Recombinant Respiratory Syncytial Virus Challenge Strain
    •
       Ref: E-235-2018-0 | Updated: Oct 25, 2018 | NIAID
  • Recombinant HIV-1 Envelope Protein for Vaccine Use
    •
       Ref: E-178-2014-0 | Updated: Oct 18, 2018 | NIAID
  • Hybridoma cell lines producing antibodies to RSV NS1
    •
       Ref: E-167-2018-0 | Updated: Oct 18, 2018 | NIAID
  • HIV-1 Env Fusion Peptide Immunogens and Their Use
    •
       Ref: E-279-2016-0 | Updated: Oct 17, 2018 | NIAID
  • Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens
    •
       Ref: E-270-2015-0 | Updated: Oct 17, 2018 | NIAID
  • Substitutions-Modified Prefusion RSV F Proteins and Their Use
    •
       Ref: E-064-2016-0 | Updated: Oct 17, 2018 | NIAID
  • Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
    •
       Ref: E-228-2016-0 | Updated: Oct 17, 2018 | NIAID
  • Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use
    •
       Ref: E-083-2017-0 | Updated: Oct 12, 2018 | NIAID
  • Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine...
    •
       Ref: E-142-2018-0 | Updated: Oct 9, 2018 | NIAID
  • Recombinant RSV B1 expressing eGFP as a reporter gene
    •
       Ref: E-159-2018-0 | Updated: Oct 9, 2018 | NIAID
  • A New Class of Immunomodulatory Drugs for Multiple Sclerosis
    •
       Ref: E-064-2015-0 | Updated: Oct 2, 2018 | NIAID
  • Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease
    •
       Ref: E-251-2016-0 | Updated: Sep 7, 2018 | NIAID
  • Prefusion HPIV F Immunogens and Their Use.
    •    Ref: E-215-2016-0 | Updated: Aug 31, 2018 | NIAID
  • Inhibition of CD300f Function on Dendritic Cells Promotes Tumor Destruction
    •
       Ref: E-257-2016-0 | Updated: Jul 23, 2018 | NIAID
  • Recombinant Paramyxoviruses Expressing Optimized Heterologous Antigens
    •
       Ref: E-241-2014-0 | Updated: Jul 3, 2018 | NIAID
  • Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection
    •
       Ref: E-045-2015-0 | Updated: Jun 22, 2018 | NIAID
  • Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
    •
       Ref: E-081-2013-0 | Updated: Jun 22, 2018 | NIAID
  • Novel Multivalent Nanoparticle Vaccines
    •
       Ref: E-060-2015-0 | Updated: Jun 22, 2018 | NIAID
  • Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein
    •
       Ref: E-300-2009-0 | Updated: Jun 22, 2018 | NIAID
  • Neutralizing Antibodies to Influenza HA and Their Use and Identification
    •
       Ref: E-061-2016-0 | Updated: Jun 22, 2018 | NIAID
  • Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof
    •
       Ref: E-066-2014-0 | Updated: Jun 22, 2018 | NIAID
  • Zika Virus Vaccines
    •
       Ref: E-181-2016-0 | Updated: Jun 22, 2018 | NIAID
  • Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic...
    •
       Ref: E-174-2016-0 | Updated: Jun 22, 2018 | NIAID
  • CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis
    •
       Ref: E-112-2016-0 | Updated: Jun 11, 2018 | NIAID
  • CCR9 Knockout Mice
    •
       Ref: E-200-2015-0 | Updated: Jun 7, 2018 | NIAID
  • Expression, Purification, and Validation of Anthrax Toxin Proteins
    •
       Ref: E-201-2015-0 | Updated: Jun 7, 2018 | NIAID
  • Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays
    •
       Ref: E-230-2014-0 | Updated: Jun 7, 2018 | NIAID
  • Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3...
    •
       Ref: E-236-2016-0 | Updated: Jun 7, 2018 | NIAID
  • CHO NL4-3 gp160
    •
       Ref: E-258-2015-0 | Updated: Jun 7, 2018 | NIAID
  • HIV-1 MW959 gp140 secreting CHO Cells
    •
       Ref: E-259-2015-0 | Updated: Jun 7, 2018 | NIAID
  • HIV-1 NL4-3 gp120 secreting CHO Cells
    •
       Ref: E-260-2015-0 | Updated: Jun 7, 2018 | NIAID
  • WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene
    •
       Ref: E-263-2015-0 | Updated: Jun 7, 2018 | NIAID
  • Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa
    •
       Ref: E-003-2016-0 | Updated: Jun 7, 2018 | NIAID
  • Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil...
    •
       Ref: E-286-2014-0 | Updated: Jun 7, 2018 | NIAID
  • Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts
    •
       Ref: E-006-2015-0 | Updated: Jun 7, 2018 | NIAID
  • Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule
    •
       Ref: E-737-2013-0 | Updated: Jun 7, 2018 | NIAID
  • Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666
    •
       Ref: E-016-2015-0 | Updated: Jun 7, 2018 | NIAID
  • pLAS-1 Plasmid
    •
       Ref: E-034-2017-0 | Updated: Jun 7, 2018 | NIAID
  • HIV-1 Clone Bal.01
    •
       Ref: E-040-2014-0 | Updated: Jun 7, 2018 | NIAID
  • RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J...
    •
       Ref: E-104-2015-0 | Updated: Jun 7, 2018 | NIAID
  • Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor
    •
       Ref: E-196-2014-0 | Updated: Jun 7, 2018 | NIAID
  • Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC...
    •
       Ref: E-145-2011-0 | Updated: May 22, 2018 | NIAID
  • HIV Monoclonal Antibodies
    •
       Ref: E-109-2008-0 | Updated: May 18, 2018 | NIAID
  • Compositions and Methods for Blocking Transmission of Plasmodium
    •
       Ref: E-294-2016-0 | Updated: May 16, 2018 | NIAID
  • T-Cell-Specific Gfi-1 Knockout Mouse
    •
       Ref: E-242-2009-0 | Updated: May 16, 2018 | NIAID
  • A Prophylactic and Therapeutic for Preventing and Treating Tularemia by Rapid Activation of Host Cells and Antigen...
    •
       Ref: E-095-2008-0 | Updated: May 16, 2018 | NIAID
  • Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-...
    •
       Ref: E-250-2005-0 | Updated: May 16, 2018 | NIAID
  • Transmission-Blocking Malaria Vaccine
    •
       Ref: E-222-2012-0 | Updated: May 16, 2018 | NIAID
  • Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy...
    •
       Ref: E-168-2016-0 | Updated: May 15, 2018 | NIAID
  • A Novel Fusion Protein for Inhibiting HIV Budding
    •
       Ref: E-223-2014-0 | Updated: May 10, 2018 | NIAID
  • Detection and Discrimination of Classical and Atypical L-Type BSE Strains by RT-QuIC
    •
       Ref: E-048-2015-0 | Updated: May 7, 2018 | NIAID
  • PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus
    •
       Ref: E-239-2007-3 | Updated: May 7, 2018 | NIAID
  • Treatment of Tuberculosis — Adjuvant Therapies to Increase the Efficiency of Antibiotics
    •
       Ref: E-189-2011-0 | Updated: May 7, 2018 | NIAID
  • Mononegavirales Vectors expressing Chimeric Antigens
    •
       Ref: E-018-2018-0 | Updated: May 7, 2018 | NIAID
  • Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
    •
       Ref: E-263-2005-0 | Updated: May 7, 2018 | NIAID
  • Multivalent Vaccines for Rabies Virus and Filoviruses
    •
       Ref: E-032-2011-0 | Updated: May 7, 2018 | NIAID
  • Diagnostic Assays and Methods of Use for Detection of Filarial Infection
    •
       Ref: E-281-2010-0 | Updated: May 6, 2018 | NIAID
  • Chlamydial Vaccine Technologies
    •
       Ref: E-031-2006-0 | Updated: Mar 28, 2018 | NIAID
  • Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
    •
       Ref: E-256-2015-0 | Updated: Feb 27, 2018 | NIAID
  • Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules
    •
       Ref: E-738-2013-0 | Updated: Dec 15, 2017 | NIAID
  • Plasmids Encoding and Producing Anthrax Toxin Proteins
    •
       Ref: E-059-2008-0 | Updated: Dec 6, 2017 | NIAID
  • Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs
    •
       Ref: E-283-2001-0 | Updated: Dec 4, 2017 | NIAID
  • Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody
    •
       Ref: B-004-1991-0 | Updated: Dec 4, 2017 | NIAID
  • Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody
    •
       Ref: B-004-1991-1 | Updated: Dec 4, 2017 | NIAID
  • Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody
    •
       Ref: B-004-1991-2 | Updated: Dec 4, 2017 | NIAID
  • Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody
    •
       Ref: B-004-1991-3 | Updated: Dec 4, 2017 | NIAID
  • Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody
    •
       Ref: B-004-1991-4 | Updated: Dec 4, 2017 | NIAID
  • Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA
    •
       Ref: B-037-1995-6 | Updated: Dec 4, 2017 | NIAID

    Pages


    Displaying 1 - 100 of 224

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057